Plantarc Bio Ltd (PLNT) - Net Assets
Based on the latest financial reports, Plantarc Bio Ltd (PLNT) has net assets worth ILA7.61 Million ILA (≈ $20.41K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA8.39 Million ≈ $22.50K USD) and total liabilities (ILA777.00K ≈ $2.08K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Plantarc Bio Ltd (PLNT) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA7.61 Million |
| % of Total Assets | 90.74% |
| Annual Growth Rate | 33.23% |
| 5-Year Change | 699.16% |
| 10-Year Change | N/A |
| Growth Volatility | 520.77 |
Plantarc Bio Ltd - Net Assets Trend (2018–2024)
This chart illustrates how Plantarc Bio Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Plantarc Bio Ltd (PLNT) total assets for the complete picture of this company's asset base.
Annual Net Assets for Plantarc Bio Ltd (2018–2024)
The table below shows the annual net assets of Plantarc Bio Ltd from 2018 to 2024. For live valuation and market cap data, see Plantarc Bio Ltd (PLNT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA9.53 Million ≈ $25.54K |
-20.34% |
| 2023-12-31 | ILA11.96 Million ≈ $32.06K |
-12.07% |
| 2022-12-31 | ILA13.60 Million ≈ $36.46K |
-23.24% |
| 2021-12-31 | ILA17.72 Million ≈ $47.50K |
+1386.24% |
| 2020-12-31 | ILA1.19 Million ≈ $3.20K |
-63.78% |
| 2019-12-31 | ILA3.29 Million ≈ $8.82K |
+93.25% |
| 2018-12-31 | ILA1.70 Million ≈ $4.57K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Plantarc Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2056200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA33.00K | 0.35% |
| Other Comprehensive Income | ILA3.82 Million | 40.06% |
| Other Components | ILA32.86 Million | 344.99% |
| Total Equity | ILA9.53 Million | 100.00% |
Plantarc Bio Ltd Competitors by Market Cap
The table below lists competitors of Plantarc Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smiths News PLC
LSE:SNWS
|
$1.96 Million |
|
Edison Lithium Corp
V:EDDY
|
$1.96 Million |
|
Nuvve Holding Corp
NASDAQ:NVVE
|
$1.97 Million |
|
Chinhung International Inc
KO:002785
|
$1.97 Million |
|
Reach PLC
LSE:RCH
|
$1.96 Million |
|
Verney-Carron S.A
PA:MLVER
|
$1.96 Million |
|
Totalindo Eka Persada Tbk PT
JK:TOPS
|
$1.95 Million |
|
Stelrad Group PLC
LSE:SRAD
|
$1.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Plantarc Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,958,000 to 9,526,000, a change of -2,432,000 (-20.3%).
- Net loss of 2,567,000 reduced equity.
- Other comprehensive income decreased equity by 1,541,000.
- Other factors increased equity by 1,676,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-2.57 Million | -26.95% |
| Other Comprehensive Income | ILA-1.54 Million | -16.18% |
| Other Changes | ILA1.68 Million | +17.59% |
| Total Change | ILA- | -20.34% |
Book Value vs Market Value Analysis
This analysis compares Plantarc Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 76.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 38.91x to 76.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ILA5.68 | ILA220.90 | x |
| 2019-12-31 | ILA10.97 | ILA220.90 | x |
| 2020-12-31 | ILA3.97 | ILA220.90 | x |
| 2021-12-31 | ILA5.35 | ILA220.90 | x |
| 2022-12-31 | ILA4.11 | ILA220.90 | x |
| 2023-12-31 | ILA3.61 | ILA220.90 | x |
| 2024-12-31 | ILA2.88 | ILA220.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Plantarc Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -58.37%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.15x
- Recent ROE (-26.95%) is above the historical average (-76.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -160.19% | 0.00% | 0.00x | 1.26x | ILA-2.90 Million |
| 2019 | -65.33% | 0.00% | 0.00x | 1.19x | ILA-2.48 Million |
| 2020 | -192.87% | 0.00% | 0.00x | 1.81x | ILA-2.42 Million |
| 2021 | -36.44% | 0.00% | 0.00x | 1.06x | ILA-8.23 Million |
| 2022 | -36.64% | -4982.00% | 0.01x | 1.12x | ILA-6.34 Million |
| 2023 | -17.63% | -44.12% | 0.36x | 1.10x | ILA-3.30 Million |
| 2024 | -26.95% | -58.37% | 0.40x | 1.15x | ILA-3.52 Million |
Industry Comparison
This section compares Plantarc Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,400,500
- Average return on equity (ROE) among peers: -772.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Plantarc Bio Ltd (PLNT) | ILA7.61 Million | -160.19% | 0.10x | $1.96 Million |
| BioLine RX Ltd (BLRX) | $50.84 Million | -40.80% | 0.50x | $9.80 Million |
| BioLight Life Sciences Ltd (BOLT) | $16.41 Million | -132.99% | 1.15x | $6.74 Million |
| Bonus Biogroup (BONS) | $6.96 Million | -399.97% | 2.36x | $128.06 Million |
| Can Fite Biopharma Ltd (CANF) | $38.70 Million | 0.00% | 0.26x | $5.75 Million |
| Clal Biotechnology Industries Ltd (CBI) | $1.26 Billion | -29.20% | 0.34x | $12.49 Million |
| Compugen (CGEN) | $19.58 Million | -61.30% | 0.49x | $208.54 Million |
| DNA Biomed Solns (DNA) | $80.11 Million | -29.38% | 0.02x | $35.00 Million |
| Enlivex Therapeutics Ltd (ENLV) | $85.04 Million | -17.01% | 0.12x | $458.60K |
| Evogene (EVGN) | $56.88 Million | -46.07% | 0.26x | $4.85 Million |
| Kadimastem Ltd (KDST) | $326.00K | -6968.71% | 37.31x | $22.18 Million |
About Plantarc Bio Ltd
PlantArc Bio Ltd. operates as an Ag-Bio company for the crop protection and yield enhancement. The company develops and operates a Direct-In-Plant gene discovery platform. It focuses on yield improvement, drought resistance, and herbicide and insects tolerance. The company was incorporated in 2014 and is based in Ra'anana, Israel.